IL17A and colitis: In our study, we found that thalidomide treatment in modeling or after modeling could reduce the overexpression of Th cell (Th1 and Th17) cytokines including IFN-γ, IGF-1, IL-6, IL-17 and TNF-α in serum and intestinal tissues in TNBS-induced colitis model.